Cittadine Andrew (CIK 1863624) reported 12 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Buy MNPR (5,254 shares), Sell MNPR (2,309 shares), Buy MNPR (3,514 shares), Sell MNPR (1,571 shares), Buy MNPR (4,326 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Buy | 5,254 | $0 |
| 2026-07-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Sell | 2,309 | $213,790 |
| 2026-04-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Buy | 3,514 | $0 |
| 2026-04-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Sell | 1,571 | $86,075 |
| 2026-01-05 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Buy | 4,326 | $0 |
| 2026-01-05 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Sell | 1,889 | $123,352 |
| 2025-10-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Buy | 4,327 | $0 |
| 2025-10-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Sell | 1,896 | $154,846 |
| 2025-07-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Buy | 6,863 | $0 |
| 2025-07-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Sell | 2,990 | $106,982 |
| 2025-04-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Buy | 1,791 | $0 |
| 2025-04-02 | Monopar Therapeutics (MNPR) | Chief Operating Officer | Sell | 744 | $27,089 |
Source: SEC Form 4 filings · as of 2026-07-02